Characteristics of Pregnant Women With Hepatitis B Virus Infection in 5 US Public Health Jurisdictions, 2008-2012.

Journal: Public health reports (Washington, D.C. : 1974)

Volume: 131

Issue: 5

Year of Publication: 2017

Affiliated Institutions:  Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Division of Viral Hepatitis, Atlanta, GA, USA. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Immunization Services Division, Atlanta, GA, USA. New York City Department of Health and Mental Hygiene, Bureau of Immunization, Perinatal Hepatitis B Prevention Unit, New York, NY, USA. Florida Department of Health, Division of Disease Control, Tallahassee, FL, USA. Michigan Department of Community Health, Division of Immunization, Lansing, MI, USA. Minnesota Department of Health, Hepatitis Unit, Cross-Cutting Section, Infectious Disease Epidemiology, Prevention and Control, St. Paul, MN, USA. Texas Department of State Health Services, ACE Unit, Immunization Branch, Austin, TX, USA.

Abstract summary 

We estimated the prevalence of hepatitis B surface antigen (HBsAg), a serologic marker of active hepatitis B virus (HBV) infection, among pregnant women, and estimated the proportion HBsAg-positive pregnant women who had received additional recommended testing.From 2008 through 2012, Perinatal Hepatitis B Prevention Programs (PHBPPs) in Florida, Michigan, Minnesota, New York City, and Texas prospectively collected data on demographic characteristics of HBsAg-positive pregnant women. We estimated the prevalence of HBsAg positivity among pregnant women by demographic characteristics using natality data. PHBPPs (excluding Texas) collected additional recommended testing (for hepatitis B e antigen [HBeAg] and/or HBV deoxyribonucleic acid [DNA]) among HBsAg-positive pregnant women to measure levels of viremia.During the study period, 15,205 HBsAg-positive women were case-managed. The median age of HBsAg-positive women was 29 years; prenatal HBsAg screening was at a median of 27 weeks pre-delivery. Of 15,205 HBsAg-positive women, 11,293 (74.3%) were foreign-born. In four PHBPPs with 14,098 pregnancies among 12,214 HBsAg-positive women, HBeAg and/or HBV DNA testing was documented for 2,794 (19.8%) pregnancies. The estimated prevalence of HBsAg positivity among pregnant women was 0.38% (17,023 of 4,468,773). HBsAg prevalence was highest among foreign-born women from most regions in Asia (2.0% to 8.7%; with the exception of South Asia, 0.4%) and Africa (3.4%).One-fifth of HBsAg-positive pregnant women had documentation for HBeAg and/or HBV DNA, and about one-third reported receiving care for HBV infection during a case-managed pregnancy. Greater emphasis is needed on prenatal evaluation for HBV liver disease care and treatment among pregnant women with HBV infection.

Authors & Co-authors:  Walker Tanja Y TY Smith Emily A EA Fenlon Nancy N Lazaroff Julie E JE Dusek Cristina C Fineis Patrick P Crowley Susan A SA Benson Ruthie R Veselsky Steven L SL Murphy Trudy V TV

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Centers for Disease Control and Prevention (US). Recommendations of the Immunization Practices Advisory Committee. Prevention of perinatal transmission of hepatitis B virus: prenatal screening of all pregnant women for hepatitis B surface antigen. MMWR Morb Mortal Wkly Rep 1988;37(22):341–6, 351.
Authors :  10
Identifiers
Doi : 10.1177/0033354916663183
SSN : 1468-2877
Study Population
Women
Mesh Terms
Adolescent
Other Terms
hepatitis B;pregnancy;women
Study Design
Cross Sectional Study
Study Approach
Country of Study
Publication Country
United States